Genomic copy number predicts esophageal cancer years before transformation.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
01
04
2020
accepted:
23
07
2020
pubmed:
9
9
2020
medline:
9
1
2021
entrez:
8
9
2020
Statut:
ppublish
Résumé
Recent studies show that aneuploidy and driver gene mutations precede cancer diagnosis by many years
Identifiants
pubmed: 32895572
doi: 10.1038/s41591-020-1033-y
pii: 10.1038/s41591-020-1033-y
pmc: PMC7116403
mid: EMS86618
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1726-1732Subventions
Organisme : Medical Research Council
ID : MC_UU_12022/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : RG84369
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Références
Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122–128 (2020).
doi: 10.1038/s41586-019-1907-7
Mitchell, T. J. et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell https://doi.org/10.1016/j.cell.2018.02.020 (2018).
Lee, J. J.-K. et al. Tracing oncogene rearrangements in the mutational history of lung adenocarcinoma. Cell https://doi.org/10.1016/j.cell.2019.05.013 (2019).
Abelson, S. et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559, 400–404 (2018).
doi: 10.1038/s41586-018-0317-6
Gregson, E. M., Bornschein, J. & Fitzgerald, R. C. Genetic progression of Barrett’s oesophagus to oesophageal adenocarcinoma. Br. J. Cancer 115, 403–410 (2016).
doi: 10.1038/bjc.2016.219
Esserman, L. J. et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 15, e234–e242 (2014).
doi: 10.1016/S1470-2045(13)70598-9
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 66, 7–30 (2016).
doi: 10.3322/caac.21332
Masclee, G. M. C., Coloma, P. M., De Wilde, M., Kuipers, E. J. & Sturkenboom, M. C. J. M. The incidence of Barrett’s oesophagus and oesophageal adenocarcinoma in the United Kingdom and the Netherlands is levelling off. Aliment. Pharmacol. Ther. 39, 1321–1330 (2014).
doi: 10.1111/apt.12759
Phoa, K. N. et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. J. Am. Med. Assoc. 311, 1209–1217 (2014).
doi: 10.1001/jama.2014.2511
Shaheen, N. J. et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N. Engl. J. Med. 360, 2277–2288 (2009).
doi: 10.1056/NEJMoa0808145
Parasa, S. et al. Development and validation of a model to determine risk of progression of Barrett’s esophagus to neoplasia. Gastroenterology 154, 1282–1289.e2 (2018).
doi: 10.1053/j.gastro.2017.12.009
Younes, M. et al. p53 protein accumulation predicts malignant progression in Barrett’s metaplasia: a prospective study of 275 patients. Histopathology 71, 27–33 (2017).
doi: 10.1111/his.13193
Pettit, K. & Bellizzi, A. Evaluation of p53 immunohistochemistry staining patterns in Barrett esophagus with low-grade dysplasia. Am. J. Clin. Pathol. 144, A382–A382 (2015).
doi: 10.1093/ajcp/144.suppl2.382
Sikkema, M. et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett’s esophagus: a case–control study. Am. J. Gastroenterol. 104, 2673–2680 (2009).
doi: 10.1038/ajg.2009.437
Keswani, R. N., Noffsinger, A., Waxman, I. & Bissonnette, M. Clinical use of p53 in Barrett’s esophagus. Cancer Epidemiol. Biomark. Prev. 15, 1243–1249 (2006).
doi: 10.1158/1055-9965.EPI-06-0010
Reid, B. J. et al. Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am. J. Gastroenterol. 96, 2839–2848 (2001).
doi: 10.1111/j.1572-0241.2001.04236.x
Alvi, M. A. et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett’s esophagus. Clin. Cancer Res. 19, 878–888 (2013).
doi: 10.1158/1078-0432.CCR-12-2880
Jin, Z. et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res. 69, 4112–4115 (2009).
doi: 10.1158/0008-5472.CAN-09-0028
Weaver, J. M. J. et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 46, 837–843 (2014).
doi: 10.1038/ng.3013
Secrier, M. et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat. Genet. 48, 1131–1141 (2016).
doi: 10.1038/ng.3659
Frankell, A. M. et al. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat. Genet. 51, 506–516 (2019).
doi: 10.1038/s41588-018-0331-5
Nones, K. et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat. Commun. 5, 5224 (2014).
doi: 10.1038/ncomms6224
Blum, A. et al. RNA sequencing identifies transcriptionally-viable gene fusions in esophageal adenocarcinomas. Cancer Res. 76, 5587–5589 (2016).
doi: 10.1158/0008-5472.CAN-16-0979
The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 https://doi.org/10.1038/nature20805 (2017).
Ross-Innes, C. S. et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett’s esophagus and esophageal adenocarcinoma. Nat. Genet. 47, 1038–1046 (2015).
doi: 10.1038/ng.3357
Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38, 468–473 (2006).
doi: 10.1038/ng1768
Martinez, P. et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett’s oesophagus. Nat. Commun. 7, 12158 (2016).
doi: 10.1038/ncomms12158
Li, X. et al. Assessment of esophageal adenocarcinoma risk using somatic chromosome alterations in longitudinal samples in Barrett’s esophagus. Cancer Prev. Res. 8, 845–856 (2015).
doi: 10.1158/1940-6207.CAPR-15-0130
Martinez, P. et al. Evolution of Barrett’s esophagus through space and time at single-crypt and whole-biopsy levels. Nat. Commun. 9, 794 (2018).
Scheinin, I. et al. DNA copy number analysis of fresh and formalin-fixed specimens by whole-genome sequencing: improved correction of systematic biases and exclusion of problematic regions. Genome Res. 24, 2022–2032 (2014).
Li, X. et al. Temporal and spatial evolution of somatic chromosomal alterations: a case–cohort study of Barrett’s esophagus. Cancer Prev. Res. 7, 114–127 (2014).
doi: 10.1158/1940-6207.CAPR-13-0289
Shaheen, N. J., Falk, G. W., Iyer, P. G. & Gerson, L. B. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am. J. Gastroenterol. 111, 30–50 (2016).
doi: 10.1038/ajg.2015.322
Fitzgerald, R. C. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 63, 7–42 (2014).
doi: 10.1136/gutjnl-2013-305372
Stachler, M. D. et al. Paired exome analysis of Barrett’s esophagus and adenocarcinoma. Nat. Genet. 47, 1047–1055 (2015).
doi: 10.1038/ng.3343
Kaye, P. V. et al. Novel staining pattern of p53 in Barrett’s dysplasia—the absent pattern. Histopathology 57, 933–935 (2010).
doi: 10.1111/j.1365-2559.2010.03715.x
Kaye, P. V. et al. Barrett’s dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology 54, 699–712 (2009).
doi: 10.1111/j.1365-2559.2009.03288.x
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
doi: 10.1093/bioinformatics/btp324
Nilsen, G. et al. Copynumber: efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics 13, 591 (2012).
doi: 10.1186/1471-2164-13-591
Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1–22 (2010).
doi: 10.18637/jss.v033.i01
Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 12, 77 (2011).
doi: 10.1186/1471-2105-12-77